Rouine-Rapp Kathryn, Mello Dennis M, Hanley Frank L, Mohan Reddy V, Soifer Scott
Department of Anesthesia and Postoperative Care, University of California, San Francisco, USA.
Pediatr Crit Care Med. 2003 Jul;4(3):327-32. doi: 10.1097/01.PCC.0000075557.41987.A3.
Hypertension in pediatric patients after surgical repair of coarctation of the aorta can be difficult to control and may lead to morbidity. The renin-angiotensin system mediates at least part of this hypertension. Enalaprilat, the only intravenous angiotensin-converting enzyme inhibitor, is used to treat hypertension in pediatric patients in other settings. However, its effect on postoperative hypertension during the early postoperative period in patients undergoing surgical repair of coarctation of the aorta is unknown.
Prospective, randomized, double-blind study.
Operating room and the pediatric intensive care unit.
Fourteen consecutive pediatric patients between the ages of 1 and 18 yrs scheduled to undergo surgical repair of coarctation of the aorta.
Patients were randomized to receive enalaprilat or saline placebo. Infusions were begun intraoperatively within 15 mins of aortic repair and repeated every 6 hrs.
Plasma renin activity was measured at baseline and on postoperative day 1. Blood pressure was determined at 30 mins and at 2, 4, and 6 hrs after infusion and scored relative to the preoperative blood pressure. The blood pressure in the enalaprilat group was consistently lower at 30 mins, 2 hrs, and 4 hrs after infusion (p <.05), but not at 6 hrs. Plasma renin activity was significantly lower in the placebo group on postoperative day 1. Length of stay in the pediatric intensive care unit trended shorter in the treated group.
Conclusions are limited by a small cohort. Angiotensin-converting enzyme inhibitor therapy resulted in improved blood pressure control after coarctation repair. Further improvement of blood pressure control may be achievable by use of a larger dose of enalaprilat or a 4-hr enalaprilat-dosing interval.
主动脉缩窄手术修复后的儿科患者高血压可能难以控制,并可能导致发病。肾素 - 血管紧张素系统介导了至少部分这种高血压。依那普利拉是唯一的静脉用血管紧张素转换酶抑制剂,在其他情况下用于治疗儿科患者的高血压。然而,其对接受主动脉缩窄手术修复的患者术后早期高血压的影响尚不清楚。
前瞻性、随机、双盲研究。
手术室和儿科重症监护病房。
14名年龄在1至18岁之间连续的计划接受主动脉缩窄手术修复的儿科患者。
患者被随机分配接受依那普利拉或生理盐水安慰剂。在主动脉修复后15分钟内术中开始输注,并每6小时重复一次。
在基线和术后第1天测量血浆肾素活性。在输注后30分钟以及2、4和6小时测定血压,并相对于术前血压进行评分。依那普利拉组在输注后30分钟、2小时和4小时时血压持续较低(p<.05),但在6小时时并非如此。安慰剂组术后第1天血浆肾素活性显著较低。治疗组在儿科重症监护病房的住院时间有缩短趋势。
由于队列较小,结论有限。血管紧张素转换酶抑制剂治疗可改善主动脉缩窄修复后的血压控制。通过使用更大剂量的依那普利拉或4小时的依那普利拉给药间隔可能实现血压控制的进一步改善。